Literature DB >> 6802332

Tamoxifen as initial sole treatment of localised breast cancer in elderly women: a pilot study.

P E Preece, R A Wood, C R Mackie, A Cuschieri.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6802332      PMCID： PMC1496321          DOI： 10.1136/bmj.284.6319.869-a

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  4 in total

1.  The treatment of operable breast cancer in the elderly female.

Authors:  H J Kesseler; J Z Seton
Journal:  Am J Surg       Date:  1978-05       Impact factor: 2.565

Review 2.  Tamoxifen in advanced breast cancer.

Authors:  H Mouridsen; T Palshof; J Patterson; L Battersby
Journal:  Cancer Treat Rev       Date:  1978-09       Impact factor: 12.111

Review 3.  Hormonal therapy of breast cancer: new approaches and concepts.

Authors:  S S Legha; H L Davis; F M Muggia
Journal:  Ann Intern Med       Date:  1978-01       Impact factor: 25.391

4.  The binding of tamoxifen to oestrogen receptor proteins under equilibrium and non-equilibrium conditions.

Authors:  R I Nicholson; J S Syne; C P Daniel; K Griffiths
Journal:  Eur J Cancer       Date:  1979-03       Impact factor: 9.162
  4 in total
  30 in total

1.  Treatment of elderly patients with breast cancer.

Authors:  J M Dixon
Journal:  BMJ       Date:  1992-04-18

2.  Poor response of breast cancer to tamoxifen.

Authors:  P J McDonald; R Carpenter; G T Royle; I Taylor
Journal:  Postgrad Med J       Date:  1990-12       Impact factor: 2.401

Review 3.  Aromatase inhibitors for breast cancer.

Authors:  Susanne Briest; Nancy E Davidson
Journal:  Rev Endocr Metab Disord       Date:  2007-09       Impact factor: 6.514

4.  A survey of the management of breast cancer in England and Wales.

Authors:  S A Harries; R N Lawrence; R Scrivener; N R Fieldman; M W Kissin
Journal:  Ann R Coll Surg Engl       Date:  1996-05       Impact factor: 1.891

Review 5.  Current Status of Neoadjuvant Endocrine Therapy in Early Stage Breast Cancer.

Authors:  Tomás Reinert; Rodrigo Gonçalves; Matthew J Ellis
Journal:  Curr Treat Options Oncol       Date:  2018-04-16

6.  Neoadjuvant endocrine treatment for breast cancer: from bedside to bench and back again?

Authors:  R R Saleh; N Bouganim; J Hilton; A Arnaout; M Clemons
Journal:  Curr Oncol       Date:  2014-02       Impact factor: 3.677

Review 7.  Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  M M Buckley; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

8.  Role of neo-adjuvant hormonal therapy in the treatment of breast cancer: a review of clinical trials.

Authors:  Catherine Abrial; Xavier Durando; Marie-Ange Mouret-Reynier; Emilie Thivat; Mathilde Bayet-Robert; Béatrice Nayl; Pascale Dubray; Christophe Pomel; Philippe Chollet; F Penault-Llorca
Journal:  Int J Gen Med       Date:  2009-07-30

Review 9.  Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool.

Authors:  Y H Chia; M J Ellis; C X Ma
Journal:  Br J Cancer       Date:  2010-08-10       Impact factor: 7.640

10.  Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial.

Authors:  Masafumi Kurosumi; Yuichi Takatsuka; Toru Watanabe; Shigeru Imoto; Hideo Inaji; Hitoshi Tsuda; Futoshi Akiyama; Goi Sakamoto; Tadashi Ikeda; Shinzaburo Noguchi
Journal:  J Cancer Res Clin Oncol       Date:  2007-12-13       Impact factor: 4.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.